Search company, investor...

Sirna Therapeutics

Founded Year



Acquired | Acquired

Total Raised




About Sirna Therapeutics

Sirna Therapeutics is a biotechnology company. It develops treatments based on ribonucleic acid (RNA) interference (RNAi) technology for asthma, diabetes, hepatitis C, macular degeneration, and more. It was founded in 1992 and is based in San Francisco, California.

Headquarters Location

185 Berry Street Suite 6504

San Francisco, California, 94107,

United States

Missing: Sirna Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sirna Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Sirna Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sirna Therapeutics is included in 2 Expert Collections, including Diabetes.



1,904 items


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Sirna Therapeutics Patents

Sirna Therapeutics has filed 144 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • Gene expression
patents chart

Application Date

Grant Date


Related Topics




MicroRNA, RNA, Molecular biology, Gene expression, RNA interference


Application Date


Grant Date



Related Topics

MicroRNA, RNA, Molecular biology, Gene expression, RNA interference



Latest Sirna Therapeutics News

Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis

May 15, 2023

USA - English Share this article Share this article SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis (also referred as severe kidney diseases). The collaboration will leverage both companies' scientific and technological expertise and will build on Rona's proprietary platform in RNAi targeting liver and extrahepatic tissues. Under the term of the collaboration, Rona will use proprietary RAZOR™ platform to discover and identify siRNA lead compounds directed to a novel target related to glomerulonephritis and Keymed will contribute research and translational expertise and capabilities. Keymed and Rona have entered into a profit/loss arrangement to further co-develop and commercialize therapeutic product candidates globally that emerge from these discovery efforts. The program is expected to enter into clinical stage in the first half of 2024. "We are looking forward to partnering with Keymed to jointly discover and develop transformative RNA therapeutics globally," said Stella SHI, the founder and CEO of Rona. "Rona's proprietary next generation siRNA platform technology and the advanced biology expertise from Keymed is a strategic fit for developing first-in-class siRNA therapeutic for devastating diseases like glomerulonephritis." "I am delightful to announce this collaboration between Keymed and Rona," said Dr. Bo CHEN, the founder and CEO of Keymed. "We keep focusing on the urgent unmet clinical needs and dedicating to provide patients with high-quality, affordable, and innovative therapies. Taking advantage of Rona's pioneering next generation siRNA platform and Keymed's sophisticated biology expertise, the collaboration will provide exciting opportunities for both companies to explore the potential targets that have not been successfully modulated through conventional therapeutic modalities." Glomerulonephritis is a prominent cause of renal impairment and constitutes 25% to 30% of all end-stage renal disease cases. Common forms of primary glomerulonephritis include IgA Nephropathy (global prevalence is ~2.5 case per 100,000 persons, with much higher prevalence in Asia), Lupus nephritis (prevalence is 8-180 cases per 100,000 persons), Membranous nephropathy (incidence of 8-10 cases per 1 million persons), etc. There is an urgent need for new medicines that treat glomerulonephritis, as there are currently few approved drugs for the disease. About Rona Therapeutics Rona Therapeutics is a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines to deliver to patients around the world. Backed by blue-chip investors, Rona has developed proprietary RAZOR™ platform to discover differentiated siRNA therapeutics from next-generation chemical modification and novel biological insights. Together with partners, Rona is dedicated to advancing transformative RNA therapeutics into clinic in metabolic syndrome, glomerulonephritis, CNS and ocular diseases. . About Keymed Biosciences Keymed Biosciences is a biotechnology company focused on the in house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. We have established a fully integrated platform encompassing all the key functions in the biologic drug development, which enabled us to rapidly and cost-effectively identify, build, expand and advance our diversified pipeline. . SOURCE Rona Therapeutics

Sirna Therapeutics Frequently Asked Questions (FAQ)

  • When was Sirna Therapeutics founded?

    Sirna Therapeutics was founded in 1992.

  • Where is Sirna Therapeutics's headquarters?

    Sirna Therapeutics's headquarters is located at 185 Berry Street, San Francisco.

  • What is Sirna Therapeutics's latest funding round?

    Sirna Therapeutics's latest funding round is Acquired.

  • How much did Sirna Therapeutics raise?

    Sirna Therapeutics raised a total of $9.9M.

  • Who are the investors of Sirna Therapeutics?

    Investors of Sirna Therapeutics include Alnylam Pharmaceuticals, Merck & Co., GGV Capital, Venrock and Sprout Group.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.